Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt (2018 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Short term Debt for 10 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 88.27% to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.3 million through Dec 2025, up 88.27% year-over-year, with the annual reading at $17.3 million for FY2025, 88.27% up from the prior year.
  • Short term Debt hit $17.3 million in Q4 2025 for Ani Pharmaceuticals, up from $15.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $25.0 million in Q2 2023 to a low of $229000.0 in Q1 2025.
  • Historically, Short term Debt has averaged $7.1 million across 5 years, with a median of $850000.0 in 2021.
  • Biggest five-year swings in Short term Debt: soared 2844.12% in 2023 and later plummeted 96.64% in 2024.
  • Year by year, Short term Debt stood at $850000.0 in 2021, then changed by 0.0% to $850000.0 in 2022, then changed by 0.0% to $850000.0 in 2023, then soared by 979.06% to $9.2 million in 2024, then skyrocketed by 88.27% to $17.3 million in 2025.
  • Business Quant data shows Short term Debt for ANIP at $17.3 million in Q4 2025, $15.2 million in Q3 2025, and $13.2 million in Q2 2025.